DelveInsight launched its new report on Bullous Pemphigoid – Market Insights, Epidemiology, and Market Forecast-2030.
DelveInsight’s “Bullous Pemphigoid – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Bullous Pemphigoid , historical and forecasted epidemiology as well as the Bullous Pemphigoid market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The key facts of the report:1. Bullous Pemphigoid is the most common type of subepidermal autoimmune bullous diseases.2. Bullous Pemphigoid highest incidences occur in the population older than 80 years of age, i.e., 150–300 cases per million people.
Key benefits of the report:1. Bullous Pemphigoid market report covers a descriptive overview and comprehensive insight of the Bullous Pemphigoid epidemiology and Bullous Pemphigoid market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Bullous Pemphigoid market report provides insights on the current and emerging therapies.3. Bullous Pemphigoid market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Bullous Pemphigoid market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Bullous Pemphigoid market.
“Bullous pemphigoid therapeutic options have been transformed significantly in the past decade.”
The key players in Bullous pemphigoid market are:1. Immune Pharmaceuticals2. Akari Therapeutics3. TWi Biotechnology4. Eli Lilly and Company
The launch of the emerging therapies is expected to significantly impact the Bullous pemphigoid treatment scenario in the upcoming years:-
Drugs covered:1. Bertilimumab2. Coversin3. AC-203
Table of contents:
1. Report Introduction2. Bullous Pemphigoid Market Overview at a Glance3. Bullous Pemphigoid Disease Background and Overview4. Bullous Pemphigoid Epidemiology and Patient Population4.1. Key Findings4.2. Population and Forecast Parameters4.3. 7MM Incident Cases of Bullous Pemphigoid (2017–2028)4.4. Total Patient Population of Bullous Pemphigoid by Regions4.4.1.United States4.4.2.EU54.4.2.1. Germany4.4.2.2. Italy4.4.2.3. Spain4.4.2.4. France4.4.2.5. United Kingdom4.4.3.Japan5. Bullous Pemphigoid Current Treatment and Medical Practices6. Bullous Pemphigoid Unmet Needs7. Bullous Pemphigoid Marketed drugs7.1. Kenketsu GLOVENIN-I (NPB-01): Nihon Pharmaceuticals8. Bullous Pemphigoid Emerging Therapies8.1. Key Cross Competition8.2. Bertilimumab: Immune Pharmaceuticals8.3. Coversin: Akari Therapeutics9. Bullous Pemphigoid Market Outlook10. 7MM: Country-Wise Market Analysis (2017–2028)10.1.United States Market Size10.2. Germany Market Size10.3. France Market Size10.4. United Kingdom Market Size10.5. Spain Market Size10.6. Italy Market Size10.7. Japan11. Market drivers12. Market barriers13. Appendix14. Bullous Pemphigoid Report Methodology15. DelveInsight Capabilities16. Disclaimer17. About DelveInsight
Related reports:
Bullous Pemphigoid Pipeline Insight, 2020
Bullous Pemphigoid – Epidemiology Forecast to 2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/